Adel Nada
Adel Nada is a highly educated professional with a diverse background in pharmaceutical medicine, internal medicine, and research & development leadership.
Adel Nada holds a Doctor of Medicine (M.D.) degree from Alexandria University and a Master of Science (M.S.) from Rush University. He also pursued advanced studies at Universität Basel in addition to his diplomas from the American Board of Internal Medicine and the University of California, San Francisco.
With extensive industry experience, Adel Nada has held key leadership roles in various prestigious organizations. He is the Co-founder, President, and CEO of GentiBio, demonstrating his entrepreneurial spirit and strategic vision. Previously, he contributed as the Chief Medical Officer at Casebia Therapeutics, Vice President & Head of Clinical Development at Intellia Therapeutics, Inc., and Vice President of Immunotherapy at Caladrius Biosciences (formerly NeoStem).
Adel Nada's expertise extends to roles such as Senior Medical Director at Baxter Healthcare, shaping cardiovascular cellular therapies, and Medical Director at Abbott Laboratories, focusing on rheumatoid arthritis global projects and clinical pharmacology. He has also served as a Director of Clinical Pharmacology Medical Department at Abbott Laboratories, overseeing cardiac safety clinical systems and pharmacogenetics.
Furthermore, Adel Nada's academic engagements include being an Assistant Professor of Internal Medicine at Rush University Medical Center and a Principal Investigator at Charles River Laboratories, highlighting his dedication to both academia and industry.
As a Member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians in the UK and a graduate of the Abbott Research & Development Leadership Program, Adel Nada combines academic rigor with practical industry knowledge to drive innovation and excellence in the field.
Adel Nada's experience spans various domains within the pharmaceutical and biotechnology sectors, showcasing his versatility, leadership acumen, and commitment to advancing medical science and healthcare solutions.